Crescent Biopharma (CBIO) Assets Average (2014 - 2026)
Crescent Biopharma (CBIO) posted quarterly Assets Average of $190.9 million for Q2 2026, up 133.68% year-over-year from $81.7 million in Q2 2025, and down 13.09% quarter-over-quarter from $219.7 million in Q1 2026.
Crescent Biopharma (CBIO) Assets Average (2014 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Assets Average for 13 consecutive years, with $190.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets Average rose 133.68% year-over-year to $190.9 million; the TTM figure through Jun 2026 stood at $190.9 million (up 133.68% YoY), while the FY2025 annual figure was $138.0 million, up 240.91% from the prior year.
- Assets Average fell to $190.9 million in Q2 2026 per CBIO's latest filing, from $219.7 million in the prior quarter.
- Across five years, Assets Average topped out at $219.7 million in Q1 2026 and bottomed at $20.1 million in Q3 2024.
- Historically, Assets Average has averaged $81.8 million across 5 years, with a median of $60.4 million in 2022.
- Annual changes were most pronounced in 2024 — Assets Average plunged 65.12% — and 2026, when it soared 956.07%.
- Crescent Biopharma's Assets Average stood at $53.9 million in 2022, then declined by 8.59% to $49.3 million in 2023, then sank by 47.91% to $25.7 million in 2024, then jumped by 637.72% to $189.3 million in 2025, then climbed by 0.88% to $190.9 million in 2026.
- Business Quant data shows CBIO's Assets Average at $190.9 million in Q2 2026, $219.7 million in Q1 2026, and $189.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 190.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 190.94 Mn |
| Mar 31, 2026 | 219.71 Mn |
| Dec 31, 2025 | 189.28 Mn |
| Sep 30, 2025 | 147.85 Mn |
| Jun 30, 2025 | 81.71 Mn |
| Mar 31, 2025 | 20.80 Mn |
| Dec 31, 2024 | 25.66 Mn |
| Sep 30, 2024 | 20.06 Mn |
| Jun 30, 2024 | 29.31 Mn |
| Mar 31, 2024 | 39.76 Mn |
| Dec 31, 2023 | 49.26 Mn |
| Sep 30, 2023 | 57.51 Mn |
| Jun 30, 2023 | 65.37 Mn |
| Mar 31, 2023 | 60.37 Mn |
| Dec 31, 2022 | 53.89 Mn |
| Sep 30, 2022 | 60.50 Mn |
| Jun 30, 2022 | 73.25 Mn |
| Mar 31, 2022 | 87.91 Mn |
| Dec 31, 2021 | 101.15 Mn |
| Sep 30, 2021 | 116.16 Mn |